Kfar-Sava, Israel Clinical Trials

A listing of Kfar-Sava, Israel clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 723 clinical trials
featured
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

www.MyelofibrosisResearch.com This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Tel Aviv Sourasky Medical Center /ID# 230311
 (9.7 away) Contact site
  • 251 views
  • 29 Apr, 2021
  • +134 other locations
featured
A Study to Evaluate the Safety Tolerability and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses of BIIB094 administered via intrathecal (IT) injection to participants with Parkinson's Disease (PD). The secondary objective of this study is to evaluate the pharmacokinetic (PK) profile of BIIB094.The study is open for …

dyskinesia
Sourasky Medical Center
 (9.7 away) Contact site
  • 250 views
  • 25 May, 2021
  • +13 other locations
featured
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases …

Meir Medical Center /ID# 221374
 (0.8 away) Contact site
  • 32 views
  • 29 Apr, 2021
  • +148 other locations
featured
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

Rabin Medical Center /ID# 219139
 (6.6 away) Contact site
  • 164 views
  • 29 Apr, 2021
  • +224 other locations
featured
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

urinary tract cancer
Research Center
 (9.8 away) Contact site
  • 1062 views
  • 08 Dec, 2020
  • +61 other locations
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

metastatic cancer
cancer
FGFR2
primary cancer
Rabin Medical Center- Beilinson Hospital
 (6.6 away) Contact site
  • 154 views
  • 14 Dec, 2020
  • +154 other locations
featured
An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Institute of Endocrinology & Metabolism Rabin Medical Center, Beilinson Campus
 (6.6 away) Contact site
  • 780 views
  • 25 Mar, 2021
  • +29 other locations
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

The purpose of this study is to evaluate the objective response rate (complete response [CR]+ partial response [PR]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.

measurable disease
dose regimen
adjuvant chemotherapy
erdafitinib
renal function
Rabin Medical Center - Bellins
 (6.6 away) Contact site
  • 40 views
  • 29 May, 2021
  • +150 other locations
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.

Sheba Medical Center - Cancer Center ( Site 0002)
 (9.0 away) Contact site
  • 742 views
  • 16 Jun, 2021
  • +52 other locations
Combination Chemotherapy With or Without Filgrastim Before Surgery High-Dose Chemotherapy and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

RATIONALE: Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of …

colony stimulating factor
cyclophosphamide
stem cell transplantation
combination chemotherapy
monoclonal antibody ch14.18
Schneider Children's Medical Center of Israel
 (6.6 away) Contact site
  • 46 views
  • 07 Nov, 2020
  • +14 other locations